Related Experiment Video
Updated: May 8, 2025
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma
Zhong Min1, Yuejie Guo1, Luo Ning1
1The First People's Hospital of Chenzhou, Chenzhou, Hunan, China.
Objective:
This study investigates the effects of Paromomycin on SUMOylation-related pathways in glioblastoma (GBM), specifically targeting HDAC1 inhibition.
Methods:
Using TCGA and GTEx datasets, we identified SUMOylation-related genes associated with GBM prognosis. Molecular docking analysis suggested Paromomycin as a potential HDAC1 inhibitor. In vitro assays on U-251MG GBM cells were performed to assess Paromomycin's effects on cell viability, SUMOylation gene expression, and IGF1R translocation using CCK8 assays, qRT-PCR, and immunofluorescence.
Results:
Paromomycin treatment led to a dose-dependent reduction in GBM cell viability, colony formation, and migration. It modulated SUMO1 expression and decreased IGF1R nuclear translocation, an effect reversible by the HDAC1 inhibitor Trochostatin A (TSA), suggesting Paromomycin's involvement in SUMO1-regulated pathways.
Conclusion:
This study highlights Paromomycin's potential as a therapeutic agent for GBM by targeting HDAC1-mediated SUMOylation pathways and influencing IGF1R translocation, warranting further investigation for its clinical application.
Insights
Paromomycin reduces glioblastoma (GBM) cell growth by inhibiting HDAC1 and affecting SUMOylation pathways. This drug shows potential for treating GBM by targeting key molecular mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- SUMOylation pathways and HDAC1 activity are implicated in GBM progression.
- Identifying novel therapeutic targets is crucial for improving GBM patient outcomes.
Purpose of the Study:
- To investigate the effects of Paromomycin on SUMOylation-related pathways in glioblastoma.
- To determine if Paromomycin acts as an inhibitor of Histone Deacetylase 1 (HDAC1).
- To explore the therapeutic potential of Paromomycin in GBM models.
Main Methods:
- Analysis of TCGA and GTEx datasets for SUMOylation-related genes in GBM.
- Molecular docking to predict Paromomycin's interaction with HDAC1.
- In vitro studies using U-251MG GBM cells to assess cell viability, gene expression, and protein translocation.
Main Results:
- Paromomycin significantly reduced GBM cell viability, colony formation, and migration in a dose-dependent manner.
- Treatment modulated SUMO1 expression and decreased Insulin-like Growth Factor 1 Receptor (IGF1R) nuclear translocation.
- The observed effects were partially reversible by Trochostatin A (TSA), a known HDAC1 inhibitor, supporting Paromomycin's mechanism of action.
Conclusions:
- Paromomycin demonstrates potential as a therapeutic agent for glioblastoma.
- The drug targets HDAC1-mediated SUMOylation pathways and influences IGF1R translocation.
- Further clinical investigation is warranted to evaluate Paromomycin's efficacy in GBM patients.
